Trustlife: new medicines, discovered with AI
Founded by the team behind the Human Protein Atlas, Trustlife uses AI to discover new medicines, with five candidates now ready for patient trials.
Trustlife is a Turkish health-technology group built around Trustlife Labs, a certified drug research and development centre in Istanbul, and Trustlife Ventures, the country’s first health-technologies venture fund. It was founded in 2021 by Bülent Denkdemir, its Chairman, together with Prof. Adil Mardinoglu, Prof. Hasan Türkez, Mehmet Uğurlu and Erkan Mankan.
Its AI-driven discovery platform designs and screens new molecules against the diseases that matter most. The pipeline counts 14 drug programmes, ten of them in cancer, and its first candidates, in Alzheimer’s disease, sarcopenia and prostate cancer, have reached the point of starting Phase I trials.
The partnership with Medixcel brings that capability to Saudi Arabia: national capacity in AI-driven drug discovery and molecular screening, and clinical trial development inside the Kingdom to international standards.
Sources: Medixcel Company Profile 2026 (candidates); Forbes Türkiye, May 2025 (programmes, experts).
Advancing localised biomedical innovation and sovereign drug development within the Kingdom.
What the partnership brings to the Kingdom
Every Saudi activity below is planned under the 2026 agreement and will be delivered with Medixcel.
Saudi-owned medicine
New medicines discovered here and owned by the Kingdom, not licensed in from abroad.
Research and trials at home
Drug research and clinical trials run inside Saudi Arabia, growing Saudi talent along the way.
AI discovery capability
Advanced national capability in AI-driven drug discovery and molecular screening, built inside the Kingdom.
Trials to international standards
Clinical trial development inside Saudi Arabia, aligned with international standards and run with Medixcel Innov and Evideep.
From agreement to Saudi capability
The programme as planned. Dates follow regulatory and construction milestones.
Partnership signed
Strategic partnership agreement signed in Riyadh in September 2026.
Localising the discovery platform
AI-driven discovery and molecular screening capability established in the Kingdom.
Saudi molecule programmes
Discovery programmes aimed at the diseases that matter most to Saudi patients, owned in the Kingdom.
Phase I trials in the Kingdom
First-in-human trials run inside Saudi Arabia with Medixcel Innov, to international standards.
Strategic partnership with Trustlife for AI drug discovery
Medixcel signed a strategic partnership agreement with Trustlife to establish national capabilities in AI-driven drug discovery, molecular screening and clinical trial development inside Saudi Arabia.